irinotecan has been researched along with platinum in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Besmaine, A; Cuvier, C; Cvitkovic, E; Dupont-André, G; Goldwasser, F; Kalla, S; Lokiec, F; Mahjoubi, M; Marty, M; Méry-Mignard, D; Misset, JL; Ouldkaci, M; Wasserman, E | 1 |
| Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
| Aiba, K; Akaza, H; Hoctin-Boes, G; Isonishi, S; Kawai, K; Konishi, T; Mikami, O; Miki, T; Noguchi, S; Ohashi, Y; Saeki, T; Saijo, N; Smith, M; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Blay, P; Buesa, JM; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Sánchez, R; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Sugiyama, T | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 1 |
| Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
| Li, J; Saif, MW | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Ford, JM; McPherson, LA; Shen, Y | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Eichbaum, C; Eichbaum, M | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Fujikawa, K; Hatachi, Y; Kato, T; Kotaka, M; Sagawa, T; Satake, H; Tsuji, A; Yasui, H | 1 |
| de Castria, TB; Fujiki, FK; Hoff, PMG; Takeda, FR; Victor, CR | 1 |
| Arnold, SM; Baggstrom, MQ; Chansky, K; Crowley, JJ; Hamm, J; Leggas, M; Rosales, J; Sanborn, RE; Thompson, MA; Villano, JL; Waqar, SN; Willis, M | 1 |
| Aprile, G; Brandi, G; Brieau, B; Casadei-Gardini, A; Dahan, L; Evesque, L; Filippi, R; Le Sourd, S; Lièvre, A; Lonardi, S; Meurisse, A; Neuzillet, C; Pointet, AL; Rousseau, B; Scartozzi, M; Silvestris, N; Tougeron, D; Vernerey, D; Vienot, A; Vivaldi, C | 1 |
| Doi, H; Ishigaki, H; Kijima, T; Kitajima, K; Koda, Y; Kuribayashi, K; Minami, T; Nakajima, Y; Nakamura, A; Takahashi, R; Yokoi, T | 1 |
| Kato, K; Matsuoka, A; Nishikimi, K; Otsuka, S; Shozu, M; Takahashi, Y; Tate, S | 1 |
| Bandyopadhyay, A; Behera, D; Sharma, S; Singh, N | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
6 review(s) available for irinotecan and platinum
| Article | Year |
|---|---|
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
[Platinum compounds in cancer therapy--past, present, and future].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Forecasting; Humans; Irinotecan; Medical Oncology; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum | 2001 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
10 trial(s) available for irinotecan and platinum
| Article | Year |
|---|---|
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Gilbert Disease; Glucuronates; Glucuronides; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Treatment Outcome | 1999 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Platinum; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids | 2018 |
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oligopeptides; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Platinum | 2021 |
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
17 other study(ies) available for irinotecan and platinum
| Article | Year |
|---|---|
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Irinotecan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Taxoids | 2003 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2012 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; DNA-Binding Proteins; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Irinotecan; MRE11 Homologue Protein; Mutation; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Real-Time Polymerase Chain Reaction | 2014 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239-124
Topics: Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Irinotecan; Platinum; Taxoids | 2018 |
Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Esophageal Neoplasms; Hospitals, Community; Humans; Irinotecan; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Female; Fluorouracil; France; Humans; Irinotecan; Italy; Male; Middle Aged; Platinum; Prospective Studies; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leukopenia; Male; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Platinum; Progression-Free Survival; Retrospective Studies; Thrombocytopenia | 2021 |
UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Platinum; Polymorphism, Genetic; Prospective Studies; Small Cell Lung Carcinoma | 2021 |